Clinical Trial Update: Study of Lenalidomide (Revlimid) in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Patients [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating lenalidomide in relapsed/refractory peripheral T-cell lymphoma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• Lenalidomide (Revlimid) (lenalidomide)

Snippet

Sponsor: University of Bologna | Conditions: Peripheral T-cell Lymphoma | Phase 2 | Status: TERMINATED